en · de · es · fr · pt
compound-index.peptides1126.com › Data › Melanotan-2 Structure And Receptor Pharmacology — Deep Dive

Melanotan-2 Structure And Receptor Pharmacology — Deep Dive

By Editorial Desk · published 2025-09-19 · last reviewed 2025-10-16 · Data

This is a working overview of freeze-thaw cycle, written for readers who want more than a one-paragraph summary but less than a textbook.

Reviewed 2025-10-16. Anything still debated is marked as such rather than presented as settled.

Melanotan-2 Structure and Receptor Pharmacology

Receptor studies place melanotan-2 among non-selective melanocortin agonists, binding MC1R, MC3R, MC4R and MC5R rather than a single subtype. Activation of MC1R on cutaneous melanocytes raises tyrosinase activity and shifts pigment synthesis toward eumelanin, which is darker and more photostable than pheomelanin. Central receptors, particularly MC4R, are associated with appetite suppression and with reported effects on sexual function. Because subtype selectivity is low, the same molecule engages pigment, metabolic and vascular pathways at once, and this breadth is a common explanation offered for the range of adverse events described in user reports.

No regulatory authority has approved melanotan-2 for human use, and several countries classify it as a prescription-only or controlled substance, which restricts lawful supply. Material sold online is generally labelled as a research chemical and is not required to meet pharmaceutical standards of identity or purity. Published human data consist mainly of small uncontrolled studies, case reports and adverse-event notifications, so the evidence base is descriptive rather than confirmatory. Whether repeated melanocyte stimulation alters long-term naevus behaviour remains an open question that no completed trial has resolved.

Melanotan-2 is a synthetic cyclic heptapeptide designed as a structural analogue of alpha-melanocyte-stimulating hormone, the endogenous tridecapeptide that regulates pigment production. Two modifications distinguish it from the natural hormone: norleucine replaces methionine at the N-terminus, which limits oxidation, and a D-phenylalanine substitution raises receptor affinity. The ring is closed through an aspartate-lysine lactam bridge, giving the molecule a constrained conformation. The free base has a molecular mass near 1024 daltons, and commercial material is usually supplied as an acetate salt. It appears in the literature as a research peptide rather than an approved therapeutic agent.

Handling, Storage and Analytical Control

Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.

Solid peptide kept dry at minus twenty degrees Celsius, shielded from light and moisture, is generally considered stable for extended periods. Solutions are divided into single-use aliquots and held at minus twenty or minus eighty degrees Celsius, because repeated freeze-thaw cycles promote aggregation and loss of material to container surfaces. Hydrolysis of the backbone and oxidation of tryptophan are the principal degradation routes in aqueous solution, and both accelerate at ambient temperature. Hygroscopic uptake after a vial is opened can also shift the actual mass weighed, which affects any concentration calculated from it.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Free base; salt forms add to total mass
Molecular massAbout 1024 daltonsCalculated for the free base
Structural classCyclic heptapeptideContains D-phenylalanine and norleucine
Parent hormoneAlpha-melanocyte-stimulating hormoneEndogenous tridecapeptide of 13 residues
Receptor profileNon-selective melanocortin agonistInteracts with MC1R, MC3R, MC4R and MC5R

Background and Receptor Mechanism

Melanotan II is a synthetic cyclic heptapeptide analog derived from the core sequence of alpha-melanocyte-stimulating hormone. Researchers at the University of Arizona synthesized it during the 1980s while studying pigmentation and appetite signaling. The compound is not an approved medicine in any major jurisdiction and appears mainly in laboratory and research-chemical settings. Its structure incorporates a lactam bridge between side chains, which constrains the ring and slows enzymatic breakdown relative to the natural hormone.

Melanotan II binds several melanocortin receptor subtypes rather than a single target. MC1R on melanocytes drives melanin synthesis, while MC3R and MC4R participate in energy balance, appetite, and sexual response pathways. This lack of selectivity explains why reported effects extend beyond skin darkening. Substitutions at positions four and seven, including norleucine and D-phenylalanine, increase potency and resistance to peptidases. Understanding which receptor mediates which effect remains an active area of investigation.

Published human data come mostly from small, short studies rather than large controlled trials. Reported outcomes include increased skin pigmentation and, in some reports, effects on appetite and libido, but sample sizes are small and follow-up is limited. Whether long-term use produces durable pigment changes or adverse effects is not established. Because products sold outside pharmacies are not standardized, the actual content of any given vial is often unknown. Independent testing of such material is uncommon.

Related pages on this site

Quality Control and Analytical Practice

Identity testing for a synthetic peptide relies on several complementary methods. Reversed-phase high-performance liquid chromatography separates the target from related impurities and reports purity as a percentage of total peak area. Mass spectrometry confirms molecular mass and can reveal deletions or truncations. Amino acid analysis and peptide mapping provide sequence-level confirmation, while counter-ion content and residual solvents are measured separately. A purity figure alone does not establish identity, so a complete dataset combines chromatographic and spectrometric evidence.

Lyophilized peptide powder is generally stored frozen, protected from light and moisture. Tryptophan residues are susceptible to oxidation, and the lactam bridge can hydrolyze under strongly acidic or basic conditions. Solutions prepared for laboratory work degrade faster than dry powder, and repeated freeze-thaw cycles accelerate loss. Common practice is to aliquot solutions before freezing and to avoid alkaline buffers. Reported stability windows vary with concentration, buffer, and temperature, so exact shelf lives are method-specific rather than universal.

Background and Mechanism of Melanotan-2

Melanotan-2, also written Melanotan II, is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence is Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, and the lactam bridge between the aspartate and lysine side chains constrains the peptide into a ring. This structural change increases receptor affinity and metabolic stability relative to the native hormone. The compound was created in the 1980s as a research tool for studying pigmentation biology.

Melanocytes are the pigment-producing cells of the skin, and they carry melanocortin-1 receptors on their surface. When the receptor is activated, cyclic adenosine monophosphate rises inside the cell and raises the activity of enzymes such as tyrosinase, which increases melanin output. Melanotan-2 binds melanocortin-1 receptors in vitro and in animal models, and this binding is generally described as the basis for the tanning effect. Other receptors account for different effects: melanocortin-4 receptors contribute to appetite and erectile signalling, while melanocortin-3 and melanocortin-5 receptors contribute to energy balance and exocrine function.

Handling, Storage, and Analytical Verification

Reversed-phase high-performance liquid chromatography is the routine method for purity assessment. Peptides absorb near 214 nm because of the peptide bond, and a gradient of acetonitrile in water separates the intact peptide from deletion sequences, oxidised products, and earlier-eluting fragments at neutral pH. Electrospray ionisation mass spectrometry provides an orthogonal check: the measured mass must agree with the theoretical value. Amino acid analysis and peptide mapping confirm structure but are used less often. Reference standards remain scarce because the peptide is not described in any pharmacopoeia.

Regulatory treatment varies by country. In the United States the peptide is not approved as a medicine, and products offered for human use may be treated as unapproved new drugs; some states also restrict sale. Australia, the United Kingdom, and European Union member states apply comparable restrictions to unapproved peptide products. Border agencies have seized shipments labelled as research chemicals. Classification may change over time, and the legal position for personal importation is not clearly settled in most published guidance.

Background from the literature

==== Chiral stationary phase (CSP) ==== In the direct enantiomer separation the most popular approach is use of chiral stationary phases. In this case the site of the chiral selector is on the stationary phase. Stationary phase consist of an inert solid support (usually silica microparticles) on to the surface of which a single enantiomer of a chiral molecule (selector) is either coated/adsorbed or chemically linked and that forms the chiral stationary phase. Commonly used chiral selectors include polysaccharides, proteins, cyclodextrins, etc. An interesting review of chiral stationary phase development and application in chiral analysis appeared in LCGC magazine, 2011.

Nuclear medicine is the use of open radionuclides for diagnostic and therapeutic purposes (radionuclide therapy). It also includes the use of other radioactive substances and nuclear physics techniques for functional and localization diagnostics. George de Hevesy (1885-1966) lived as a lodger and in 1923 suspected that his landlady was offering him pudding that he had not eaten the following week. He mixed a small amount of a radioactive isotope into the leftovers. When she served him the pudding a week later, he was able to detect radioactivity in a sample of the casserole. When he showed this to his landlady, she immediately gave him notice. The method he used made him the father of nuclear medicine. It became known as the tracer method, which is still used today in nuclear medicine diagnostics. A small amount of a radioactive substance, its distribution in the organism, and its path through the human body can be tracked externally. This provides information about various metabolic functions of the body. The continuous development of radionuclides has improved radiation protection. For example, the mercury compounds 203chloro-merodrin and 197chloro-merodrin were abandoned in the 1960s as substances were developed that allowed a higher photon yield with less radiation exposure. Beta emitters such as 131I and 90Y are used in radionuclide therapy. In nuclear medicine diagnostics, the beta+ emitters 18F, 11C, 13N, and 15O are used as radioactive markers for tracers in positron emission tomography (PET).

=== Aneuploidy === Sex chromosomes Analysis of maternal serum cffDNA by high-throughput sequencing can detect common fetal sex chromosome aneuploidies such as Turner's syndrome, Klinefelter's syndrome and triple X syndrome but the procedure's positive predictive value is low.

Sources: en.wikipedia.org

Reference notes

== Structure == Lipoprotein(a) [Lp(a)] consists of an LDL-like particle and the specific apolipoprotein(a), which is bound covalently to the apoB contained in the outer shell of the particle. Lp(a) plasma concentrations are highly heritable and mainly controlled by the LPA gene located on chromosome 6q25.3–q26. Apo(a) proteins vary in size due to a size polymorphism [KIV-2 VNTR], which is caused by a variable number of kringle IV repeats in the LPA gene. This size variation at the gene level is expressed on the protein level as well, resulting in apo(a) proteins with 10 to more than 50 kringle IV repeats (each of the variable kringle IV consists of 114 amino acids). These variable apo(a) sizes are known as "apo(a) isoforms". There is a general inverse correlation between the size of the apo(a) isoform and the Lp(a) plasma concentration. One theory explaining this correlation involves different rates of protein synthesis. Specifically, the larger the isoform, the more apo(a) precursor protein accumulates intracellularly in the endoplasmic reticulum. Lp(a) is not fully synthesised until the precursor protein is released from the cell, so the slower production rate for the larger isoforms limits the plasma concentration.

The properties of phalloidin make it a useful tool for investigating the distribution of F-actin in cells by labeling phalloidin with fluorescent analogs and using them to stain actin filaments for light microscopy. Fluorescent derivatives of phalloidin have turned out to be enormously useful in localizing actin filaments in living or fixed cells as well as for visualizing individual actin filaments in vitro. A high-resolution technique was developed to detect F-actin at the light and electron microscopic levels by using phalloidin conjugated to the fluorophore eosin which acts as the fluorescent tag. In this method known as fluorescence photo-oxidation, fluorescent molecules can be utilized to drive the oxidation of diaminobenzidine (DAB) to create a reaction product that can be rendered electron dense and detectable by electron microscopy. The amount of fluorescence visualized can be used as a quantitative measure of the amount of filamentous actin there is in cells if saturating quantities of fluorescent phalloidin are used. Consequently, immunofluorescence microscopy along with microinjection of phalloidin can be used to evaluate the direct and indirect functions of cytoplasmic actin in its different stages of polymer formation. Therefore, fluorescent phalloidin can be used as an important tool in the study of actin networks at high resolution.

dodecapeptide located in the C-terminal of the fibrinogen γ chain (the most important) RGD sequence of the α chain → the Arginine-Glycine-Aspartate amino acid sequence This complex also binds vWF, fibronectin and vitronectin. In the resting state the contact between the two protein subunits (necessary for the complex activation) is prevented by aggregin, which disables their contact necessary for the complex activation. The complex can be activated by ADP. When bound to ADP, conformational changes occur within the aggregin molecule and consequently, it dissociates from the two subunits. Furthermore, the complex can be activated by thrombin. Thrombin binding to its receptor activates protein kinase C and increases the level of inositol triphosphate. Consequently, there is a release of calcium ions that activate calpain. Calpain cleaves aggregin, and thus allows for joining of the two subunits. Deficiency in the IIb / IIIa complex is described as Glanzmann's thrombasthenia. Patients completely lack the ability to aggregate platelets.

Sources: en.wikipedia.org

Reference notes

== Medical uses == Imipenem/cilastatin is used for lower respiratory tract infections, urinary tract infections, intra-abdominal infections, gynecologic infections, bacterial sepsis, bone and joint infections, skin and skin structure infections, endocarditis and polymicrobic infections. It is a broad-spectrum beta-lactam containing equal quantities of imipenem and cilastatin.

=== Phylogenetic tree topologies and other parameters === Phylogenetic tree topologies are often the parameter of interest; thus, branch lengths and any other parameters describing the substitution process are often viewed as nuisance parameters. However, biologists are sometimes interested in the other aspects of the model. For example, branch lengths, especially when those branch lengths are combined with information from the fossil record and a model to estimate the timeframe for evolution. Other model parameters have been used to gain insights into various aspects of the process of evolution. The Ka/Ks ratio (also called ω in codon substitution models) is a parameter of interest in many studies. The Ka/Ks ratio can be used to examine the action of natural selection on protein-coding regions, it provides information about the relative rates of nucleotide substitutions that change amino acids (non-synonymous substitutions) to those that do not change the encoded amino acid (synonymous substitutions).

A total of 94 F4U-7s were built for the Aéronavale in 1952, with the last of the batch, the final Corsair built, rolled out in December 1952. The F4U-7s were actually purchased by the U.S. Navy and passed on to the Aéronavale through the U.S. Military Assistance Program (MAP). They were supplemented by 25 ex-U.S.MC AU-1s (previously used in the Korean War) and moved from Yokosuka, Japan, to Tourane Air Base (Da Nang), Vietnam, in April 1952. US Air Force assistance followed in November 1953 when the French commander in Indochina, General Henri Navarre, asked General Chester E. McCarty, commander of the Combat Cargo Division, for 12 Fairchild C-119s for Operation Castor at Dien Bien Phu. The USAF also provided C-124 Globemasters to transport French paratroop reinforcements to Indochina. Under the codename Project Swivel Chair, on March 3, 1954, 12 C-119s of the 483rd Troop Carrier Wing ("Packet Rats") based at Ashiya, Japan, were painted with France's insignia and loaned to France with 24 CIA pilots for short-term use. Maintenance was carried out by the US Air Force and airlift operations were commanded by McCarty.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan-2 approved for medical use?

No regulatory agency has authorised melanotan-2 as a medicine for any indication. It circulates mainly as a research chemical or through unregulated channels. As a result, identity, purity and content are not independently guaranteed.

How does melanotan-2 differ from melanotan-1?

Melanotan-1, also called afamelanotide, is a linear analogue with greater selectivity for MC1R and has received approval in some jurisdictions for a specific photosensitivity disorder. Melanotan-2 is cyclic, less selective, and reaches central receptors more readily. The two are often confused in online discussion despite different pharmacology and regulatory status.

What is the connection to alpha-MSH?

Alpha-MSH is an endogenous tridecapeptide derived from pro-opiomelanocortin. Melanotan-2 reproduces its core receptor-binding sequence inside a shortened, stabilised ring. The result is a molecule with a longer effective half-life and higher potency than the parent hormone.

How is peptide purity usually reported?

Purity is normally stated as an area percentage from high-performance liquid chromatography, for example ninety-five or ninety-eight percent. That figure describes the proportion of ultraviolet-absorbing material eluting as the main peak. It says nothing about water content, counterions, residual solvents or mass fraction of the peptide itself.

Network